Zobrazeno 1 - 10
of 122
pro vyhledávání: '"Olga, Salamero"'
Autor:
Teresa Bernal, Ainhoa Fernández Moreno, Almudena de LaIglesia, Celina Benavente, Ana García‐Noblejas, Daniel García Belmonte, Rosalía Riaza, Olga Salamero, Maria Angeles Foncillas, Alicia Roldán, Víctor Noriega Concepción, Laura Llorente González, Juan Miguel Bergua Burgués, Soraya Lorente de Uña, Gabriela Rodríguez‐Macías, Adolfo de la Fuente Burguera, Maria José García Pérez, Jose Luis López‐Lorenzo, Pilar Martínez, Concepción Aláez, Marta Callejas, Carmen Martínez‐Chamorro, José Rifón Roca, Lourdes Amador Barciela, Armando V. Mena Durán, Karoll Gómez Correcha, Esperanza Lavilla Rubira, María Luz Amigo, Ferran Vall‐llovera, Ana Garrido, María García‐Fortes, Dunia de Miguel Llorente, Anastasia Aules Leonardo, Carlos Cervero, Rosa Coll Jordá, Manuel M. Pérez‐Encinas, Marta Polo Zarzuela, Angela Figuera, Guillermo Rad, David Martínez‐Cuadrón, Pau Montesinos
Publikováno v:
Cancer Medicine, Vol 12, Iss 14, Pp 14892-14901 (2023)
Abstract Background CPX‐351 is approved for the treatment of therapy related acute myeloid leukemia (t‐AML) and AML with myelodysplastic related changes (MRC‐AML). The benefits of this treatment over standard chemotherapy has not been addressed
Externí odkaz:
https://doaj.org/article/9c1db4405e274742a000602740ddeff0
Autor:
Guadalupe Oñate, Marta Pratcorona, Ana Garrido, Alicia Artigas-Baleri, Alex Bataller, Mar Tormo, Montserrat Arnan, Susana Vives, Rosa Coll, Olga Salamero, Ferran Vall-Llovera, Antònia Sampol, Antoni Garcia, Marta Cervera, Sara Garcia Avila, Joan Bargay, Xavier Ortín, Josep F. Nomdedéu, Jordi Esteve, Jorge Sierra, Spanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias (CETLAM)
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Midostaurin added to intensive chemotherapy is the standard of care for acute myeloid leukemia (AML) with FLT3 mutations (FLT3mut). We analyzed the impact of midostaurin in 227 FLT3mut-AML patients included in the AML-12 prospective trial fo
Externí odkaz:
https://doaj.org/article/44faeaa66ec84739ae0950e1c8e25bf3
Autor:
Michael Boyiadzis, Pinkal Desai, Nikki Daskalakis, William Donnellan, Lucille Ferrante, Jenna D. Goldberg, Michael R. Grunwald, Christina Guttke, Xiang Li, Jose Antonio Perez‐Simon, Olga Salamero, Trevor Tucker, Xiaoying Xu, Jay Yang, Naveen Pemmaraju, Juan Manuel Alonso‐Dominguez
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 3, Pp 429-435 (2023)
Abstract This study aimed to identify a recommended phase II dose and evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary clinical activity of JNJ‐63709178, a CD123/CD3 dual‐targeting antibody, in patients with r
Externí odkaz:
https://doaj.org/article/2ed30f1b9d9b4b9aad49fe1caf9fdf6d
Autor:
Pau Montesinos, Rebeca Rodríguez-Veiga, Juan Miguel Bergua Burgues, Lorenzo Algarra, Carmen Botella, Perez Simon Josè Antonio, Teresa Bernal, Mar Tormo, Maria Calbacho Robles, Olga Salamero, Josefina Serrano, Victor Noriega, Juan Antonio López-López, Susana Vives Polo, Mercedes Colorado, Jose Luis Lopez Lorenzo, María Belén Vidriales, Raimundo Garcia Boyero, Mayte Olave, Pilar Herrera-Puente, Olga Arce, Manuel Barrios Garcia, Maria Jose Sayas Lloris, Marta Polo, Maria Isabel Gomez Roncero, Eva Barragan, Rosa Ayala Diaz, Maria Carmen Chillon, Maria Jose Calasanz, Blanca Boluda, David Martinez-Cuadrón, Jorge Labrador
Publikováno v:
HemaSphere, Vol 7, p e734771d (2023)
Externí odkaz:
https://doaj.org/article/042f02867fdf469c8ffe23116a253b38
Autor:
Marta Sobas, Wanda Knopinska-Posluszny, Beata Piątkowska-Jakubas, Gert Ossenkoppele, Flor García-Álvarez, María Elena Amutio Díez, Mar Caballero, David Martinez-Cuadrón, Eliana Aguiar, Jose Gonzalez Campos, Ana Garrido Diaz, Lorenzo Algarra, Olga Salamero, Javier de la Serna, Maria Jose Sayas Lloris, Manuel Mateo Perez Encinas, Susana Vives Polo, Veronica Gonzalez DE LA Calle, Jorge Labrador, Ana Inés Prado, Lucía Celebrin, Jiri Mayer, Graca Luiza O P Neto Vasconcelos Esteves, Almudena de Laiglesia, Juan Miguel Bergua Burgues, Maria Luz Amigo, Carlos Rodriguez Medina, Marta Polo, Agnieszka Pluta, Edyta Cichocka, Marek Skarupski, Miguel A Sanz, Pau Montesinos
Publikováno v:
HemaSphere, Vol 7, p e835897e (2023)
Externí odkaz:
https://doaj.org/article/3a432e023ec64f9b909b8f6687c1d75f
Autor:
Amir Fathi, Eunice Wang, Ghayas Issa, Jessica Altman, Pau Montesinos, Stéphane de Botton, Roland Walter, Kirsten Pettit, Mrinal Patnaik, Marina Kremyanskaya, Maria Baer, James M Foran, Gary Schiller, Lionel Ades, Maël Heiblig, Pierre Peterlin, Olga Salamero Garcia, Cristina Papayannidis, Kun Nie, Julie Ahsan Mackey, Marilyn Tabachri, Daniel Corum, Mollie Leoni, Stephen Dale, Harry Erba
Publikováno v:
HemaSphere, Vol 7, p e19161da (2023)
Externí odkaz:
https://doaj.org/article/8e09726e3c94452db7d4ebd57a3010e3
Autor:
Hartmut Döhner, Argiris Symeonidis, Dries Deeren, Judit Demeter, Miguel A. Sanz, Achilles Anagnostopoulos, Jordi Esteve, Walter Fiedler, Kimmo Porkka, Hee-Je Kim, Je-Hwan Lee, Kensuke Usuki, Stefano D'Ardia, Chul Won Jung, Olga Salamero, Heinz-August Horst, Christian Recher, Philippe Rousselot, Irwindeep Sandhu, Koen Theunissen, Felicitas Thol, Konstanze Döhner, Veronica Teleanu, Daniel J. DeAngelo, Tomoki Naoe, Mikkael A. Sekeres, Valerie Belsack, Miaomiao Ge, Tillmann Taube, Oliver G. Ottmann
Publikováno v:
HemaSphere, Vol 5, Iss 8, p e617 (2021)
In this phase 3 trial, older patients with acute myeloid leukemia ineligible for intensive chemotherapy were randomized 2:1 to receive the polo-like kinase inhibitor, volasertib (V; 350 mg intravenous on days 1 and 15 in 4-wk cycles), combined with l
Externí odkaz:
https://doaj.org/article/f447c1cf31de4bcc96ad51294c483c91
Autor:
Johana, Díaz-Santa, Rocío, Rodríguez-Romanos, Rosa, Coll, Gemma, Osca, Marta, Pratcorona, Marta, González-Bártulos, Ana, Garrido, Anna, Angona, Carme, Talarn, Mar, Tormo, Montserrat, Arnan, Susanna, Vives, Olga, Salamero, Esperanza, Tuset, Natàlia, Lloveras, Isabel, Díez, Lurdes, Zamora, Joan, Bargay, Antonia, Sampol, David, Cruz, Jordi, Vila, Marta, Sitges, Antoni, Garcia, Ferran, Vall-Llovera, Jordi, Esteve, Jorge, Sierra, David, Gallardo
Publikováno v:
European Journal of Haematology. 109:755-764
Acute myeloid leukemia (AML) is a complex disease, and its treatment needs to be adjusted to the risk, which is conferred by cytogenetics and molecular markers. Cytarabine is the main drug to treat AML, and it has been suggested that the genotype of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d17fcc6a25d404ee62a969134f92f161
https://doi.org/10.1111/ejh.13862
https://doi.org/10.1111/ejh.13862
Autor:
Teresa Bernal, Ainhoa Fernández Moreno, Almudena de LaIglesia, Celina Benavente, Ana García‐Noblejas, Daniel García Belmonte, Rosalía Riaza, Olga Salamero, Maria Angeles Foncillas, Alicia Roldán, Víctor Noriega Concepción, Laura Llorente González, Juan Miguel Bergua Burgués, Soraya Lorente de Uña, Gabriela Rodríguez‐Macías, Adolfo de la Fuente Burguera, Maria José García Pérez, Jose Luis López‐Lorenzo, Pilar Martínez, Concepción Aláez, Marta Callejas, Carmen Martínez‐Chamorro, José Rifón Roca, Lourdes Amador Barciela, Armando V. Mena Durán, Karoll Gómez Correcha, Esperanza Lavilla Rubira, María Luz Amigo, Ferran Vall‐llovera, Ana Garrido, María García‐Fortes, Dunia de Miguel Llorente, Anastasia Aules Leonardo, Carlos Cervero, Rosa Coll Jordá, Manuel M. Pérez‐Encinas, Marta Polo Zarzuela, Angela Figuera, Guillermo Rad, David Martínez‐Cuadrón, Pau Montesinos
Publikováno v:
Cancer Medicine.
Background CPX-351 is approved for the treatment of therapy related acute myeloid leukemia (t-AML) and AML with myelodysplastic related changes (MRC-AML). The benefits of this treatment over standard chemotherapy has not been addressed in well matche
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08aaa69d252127d680f5d110b0361f89
https://doi.org/10.1002/cam4.6120
https://doi.org/10.1002/cam4.6120
Autor:
Francesc Bosch, Marta Crespo, Susana G. Kalko, Eva Giné, Carles Codony, Eva Fernández, Olga Salamero, Pau Abrisqueta, Eva Calpe, Ana Muntañola, Maria Joao Baptista
PDF file, 290K, Clinico-biological characteristics and response to dexamethasone of the series of patients with CLL.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e4a6e4aa7d50a16ce41caa540d98ec0
https://doi.org/10.1158/1078-0432.22443657
https://doi.org/10.1158/1078-0432.22443657
